Novel bi-specific immunotherapeutic against high-threat Gram-negative pathogens
针对高威胁革兰氏阴性病原体的新型双特异性免疫疗法
基本信息
- 批准号:10337197
- 负责人:
- 金额:$ 114.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-02-21 至 2024-01-31
- 项目状态:已结题
- 来源:
- 关键词:AcinetobacterAcinetobacter baumanniiAcinetobacter baumannii pneumoniaAcuteAddressAdverse effectsAnti-Bacterial AgentsAntibodiesAntibody-drug conjugatesAntimicrobial ResistanceBacteriaBacterial InfectionsBindingBrucellaCardiovascular systemCellsCenters for Disease Control and Prevention (U.S.)Cessation of lifeClinicalColistinCollaborationsColony-forming unitsComplement-Dependent CytotoxicityDevelopmentDoseDose FractionationDrug KineticsDrug resistanceEnterobacterEnvironmentEscherichia coliEvaluationFc domainFormulationFrancisella tularensisGoalsHalf-LifeHealth Care CostsHealth systemHourHumanIgG1ImmuneImmune responseImmune systemImmunologicsImmunotherapeutic agentIn VitroInfectionInfection preventionInvestigational DrugsKidneyKlebsiellaKlebsiella pneumoniaeLeadLifeLipopolysaccharidesLung infectionsMacaca fascicularisMalignant NeoplasmsMediatingMethodsMicrobiologyModelingMonkeysMulti-Drug ResistanceMusMutationNatureNew AgentsNew JerseyPeptidesPhagocytosisPharmaceutical PreparationsPharmacologyPharmacology StudyPharmacology and ToxicologyPlasmaPropertyProphylactic treatmentPseudomonasPseudomonas aeruginosaPublic HealthRattusResistanceRodentSafetySepsisSepticemiaSolubilitySystemic infectionTherapeuticTherapeutic AgentsTimeTissuesToxicokineticsToxicologyTreatment EfficacyUnited StatesUniversitiesValidationWhole BloodWorkYersinia pestisantibody-dependent cell cytotoxicityantimicrobialantimicrobial drugarmbacterial resistancebasecell killingclinical efficacycolistin resistancedimerdrug candidatedrug metabolismdrug synthesisexperimental studyhigh risk populationimprovedin vivoinnovationlead seriesmedical schoolsmouse modelneonatal Fc receptornovelpathogenpathogenic bacteriapreventprogramsprophylacticreceptorreceptor bindingresistant strainrespiratorysafety studyscreeningstandard of care
项目摘要
The Centers for Disease Control and Prevention estimates that at least two million illnesses and 23,000 deaths
annually are caused by antimicrobial-resistant bacteria in the United States. The Gram-negative (G-) pathogens
are of particular concern, as they account for roughly 99,000 deaths and $20B in health care costs a year.
Treatment options for G- infections have become increasingly limited due to rapid emergence of multi-drug
resistance (MDR) to existing and newly approved antimicrobial agents, highlighting the need for alternative
strategies to prevent MDR G- infections. Further, although it’s rare, MDR can potentially be a serious problem in
G- Select Agents, given the highly transmissible nature of the MDR determinants in G- bacteria and the fact that
select agents are persisting in the environment. Thus, a broad spectrum agent that leverages immunological
mechanisms to prevent as well as to treat high-threat G- bacterial infections in high risk populations
would possess a unique advantage in addressing this need. The innovative Cloudbreak™ Antibody Drug
Conjugates (ADCs) platform, developed at Cidara Therapeutics, is a broad-spectrum G- active drug candidate
that uses a fundamentally new immune-based approach to prevent and treat G- infections. Similar to successful
cancer bispecific agents, ADCs bind conserved targets on pathogens via a Targeting Moiety (TM) while
simultaneously engaging multiple arms of the immune system via an Effector Moiety (EM). The TM is comprised
of a dimeric peptide that binds tightly to lipopolysaccharide (LPS) and confers broad spectrum G- coverage with
potent intrinsic antimicrobial activity. The EM is a human IgG1 Fc, which collectively activates complement
dependent cytotoxicity (CDC), antibody (Ab)-dependent cell-mediated cytotoxicity (ADCC), and Ab-dependent
cell phagocytosis (ADCP) to clear high-threat G- pathogens from the host, via recognition by Fcγ receptors on
host cells. This innovative approach involving efficient cell targeting with inherent cell killing catalyzes a robust
immune response by more effectively presenting the pathogen to immune components for clearance. CTC-026
is our lead ADC candidate and has demonstrated highly promising properties as an immunoprophylactic and
therapeutic agent: broad spectrum antibacterial activity that is both intrinsic and immune-driven, acute safety in
rodents, in vivo efficacy in mouse models of Escherichia coli sepsis and Acinetobacter baumannii pneumonia,
and a 67 hour plasma half-life in mice. Further optimization of potency and spectrum and in-depth evaluation of
pharmacological and toxicological properties of this lead are proposed in this application. The overarching goal
of this proposal is to identify a qualified lead development candidate in Year 3 and an Investigational new drug
(IND) candidate by the end of Year 5, that meets these criteria: 1) acceptable stability and solubility for IV
formulation, 2) MIC90s ≤1 µM against clinical isolates (including MDR) of Klebsiella, Acinetobacter,
Pseudomonas, E. coli and select agents Francisella tularensis, Yersinia pestis and Brucella species, 3) MIC90s
≤1 µM against MCR-1, MCR-2 and other colistin-resistant G- clinical isolates, 4) robust in vivo prophylactic
efficacy against MDR G- infections in a time window 48-72h prior to infection, and potent therapeutic efficacy
better than standard of care with a ≥3-fold therapeutic window after the infection, 5) PK/PD parameters to support
once weekly or better dosing in humans, 6) a NOAEL in GLP toxicology studies in rats and Cynomolgus monkeys
at least fivefold higher than the targeted clinical dose, and 7) a scalable synthesis to GMP product.
疾病控制和预防中心估计,至少有200万人患病,2.3万人死亡
在美国,每年都是由抗菌素耐药性细菌引起的。革兰阴性(G-)病原菌
尤其令人担忧,因为它们每年造成约9.9万人死亡,医疗保健成本高达200亿美元。
由于多种药物的迅速出现,G感染的治疗选择变得越来越有限
对现有和新批准的抗菌剂的耐药性(MDR),突出了替代药物的必要性
预防耐多药G-感染的策略。此外,尽管MDR很少见,但它可能是一个严重的问题
G-选择剂,鉴于G-细菌中MDR决定簇的高度传播性,以及
选定的代理在环境中持续存在。因此,一种利用免疫学的广谱制剂
预防和治疗高危人群高危G-细菌感染的机制
将在满足这一需求方面拥有独特的优势。创新的CloudBreak™抗体药物
Cidara Treeutics开发的共轭化合物(ADC)平台是一种广谱G活性候选药物
这使用了一种全新的基于免疫的方法来预防和治疗G感染。类似于成功
癌症双特异性药物,ADC通过靶向部分(TM)将保守的靶点结合在病原体上,而
通过效应器部分(EM)同时接触免疫系统的多个手臂。TM包括
一种与脂多糖(LPS)紧密结合并提供广谱G-覆盖的二聚体多肽
强大的内在抗菌活性。EM是人类的IgG1Fc,它集体激活补体
依赖细胞毒作用(CDC)、抗体依赖细胞介导的细胞毒作用(ADCC)和抗体依赖细胞毒作用
细胞吞噬作用,通过Fcγ受体的识别,从宿主中清除高威胁的G病原体
宿主细胞。这种创新的方法涉及到高效的细胞靶向和固有的细胞杀伤,催化了强大的
通过更有效地将病原体呈现给免疫组件以进行清除,从而实现免疫反应。CTC-026
是我们的主要ADC候选者,并显示出非常有前途的免疫预防和
治疗剂:广谱抗菌活性,既有内在的,也有免疫驱动的,急性安全性
啮齿动物对大肠杆菌败血症和鲍曼不动杆菌肺炎小鼠模型的体内疗效,
小鼠的血浆半衰期为67小时。进一步优化药效和频谱,深入评估
在这一应用中,提出了该铅的药理和毒理性质。首要目标是
这项提议的目的是在第三年确定一名合格的领先开发候选人和一种研究新药
(IND)候选人,在第5年年底前,满足以下标准:1)IV的可接受稳定性和溶解度
制剂,2)对临床分离的克雷伯氏菌、不动杆菌、
假单胞菌、大肠埃希氏菌和选择性图拉氏菌、鼠疫耶尔森菌和布鲁氏菌,3)MIC90
≤1微米抗Mcr-1、Mcr-2和其他粘菌素耐药G-临床分离株,4)体内强大的预防
在感染前48-72小时的时间窗内对耐多药G-感染的疗效,以及强大的治疗效果
感染后≥3倍治疗窗优于标准护理,5)PK/PD参数支持
在人类中每周一次或更好的剂量,6)大鼠和食蟹猴GLP毒理学研究中的NOAEL
至少比临床目标剂量高五倍,以及7)GMP产品的可扩展合成。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David S Perlin其他文献
Worldwide emergence of fluconazole-resistant emCandida parapsilosis/em: current framework and future research roadmap
全球氟康唑耐药近平滑念珠菌的出现:当前框架和未来研究路线图
- DOI:
10.1016/s2666-5247(23)00067-8 - 发表时间:
2023-06-01 - 期刊:
- 影响因子:20.400
- 作者:
Farnaz Daneshnia;João N de Almeida Júnior;Macit Ilkit;Lisa Lombardi;Austin M Perry;Marilyn Gao;Clarissa J Nobile;Matthias Egger;David S Perlin;Bing Zhai;Tobias M Hohl;Toni Gabaldón;Arnaldo Lopes Colombo;Martin Hoenigl;Amir Arastehfar - 通讯作者:
Amir Arastehfar
David S Perlin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David S Perlin', 18)}}的其他基金
Accelerated development of advanced leads against SARS-CoV-2 and other pandemic viruses
加速开发针对 SARS-CoV-2 和其他大流行病毒的先进先导药物
- 批准号:
10513922 - 财政年份:2022
- 资助金额:
$ 114.2万 - 项目类别:
A CETR-based partnership accelerator for rapid drug development targeting SARS-CoV-2 and pan-CoVs
基于 CETR 的合作加速器,用于针对 SARS-CoV-2 和泛冠状病毒的快速药物开发
- 批准号:
10187269 - 财政年份:2020
- 资助金额:
$ 114.2万 - 项目类别:
Critical Factors Influencing Echinocandin Resistance in Candidaglabrata
影响光滑念珠菌棘白菌素耐药性的关键因素
- 批准号:
10451830 - 财政年份:2019
- 资助金额:
$ 114.2万 - 项目类别:
Center to develop innovative therapeutics to multidrug resistant high-threat bacterial agents
开发针对多重耐药高威胁细菌制剂的创新疗法的中心
- 批准号:
10394984 - 财政年份:2019
- 资助金额:
$ 114.2万 - 项目类别:
Novel bi-specific immunoprophylactics against multi-drug resistant Gram-negativebacterial infections
针对多重耐药革兰氏阴性细菌感染的新型双特异性免疫预防剂
- 批准号:
10380759 - 财政年份:2019
- 资助金额:
$ 114.2万 - 项目类别:
Novel bi-specific immunoprophylactics against multi-drug resistant Gram-negative bacterial infections
针对多重耐药革兰氏阴性细菌感染的新型双特异性免疫预防剂
- 批准号:
9898899 - 财政年份:2019
- 资助金额:
$ 114.2万 - 项目类别:
Critical Factors Influencing Echinocandin Resistance in Candidaglabrata
影响光滑念珠菌棘白菌素耐药性的关键因素
- 批准号:
10215271 - 财政年份:2019
- 资助金额:
$ 114.2万 - 项目类别:
相似海外基金
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 114.2万 - 项目类别:
Research Grant
Generative machine learning for narrow spectrum antibiotic discovery against Acinetobacter baumannii
生成机器学习用于发现针对鲍曼不动杆菌的窄谱抗生素
- 批准号:
477936 - 财政年份:2023
- 资助金额:
$ 114.2万 - 项目类别:
Operating Grants
Conserved structural dynamics of outer-membrane channels in Acinetobacter baumannii as potential drug targets
鲍曼不动杆菌外膜通道的保守结构动力学作为潜在的药物靶点
- 批准号:
494854 - 财政年份:2023
- 资助金额:
$ 114.2万 - 项目类别:
Operating Grants
Defining key players at the host-pathogen interface during Acinetobacter baumannii infection
定义鲍曼不动杆菌感染期间宿主-病原体界面的关键参与者
- 批准号:
488684 - 财政年份:2023
- 资助金额:
$ 114.2万 - 项目类别:
Operating Grants
Study of clinically over-expressed and chimeric RND multidrug efflux pumps from Acinetobacter baumannii and Pseudomonas aeruginosa
鲍曼不动杆菌和铜绿假单胞菌临床过表达和嵌合 RND 多药外排泵的研究
- 批准号:
23K14346 - 财政年份:2023
- 资助金额:
$ 114.2万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Biomimetic Macrophage Membrane-Coated Nanosponges: A Novel Therapeutic for Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii Hospital-Associated Pneumonia
仿生巨噬细胞膜包被的纳米海绵:一种治疗多重耐药铜绿假单胞菌和鲍曼不动杆菌医院相关肺炎的新疗法
- 批准号:
10674406 - 财政年份:2023
- 资助金额:
$ 114.2万 - 项目类别:
Using strain history to improve prediction of the evolution of antimicrobial resistance in Acinetobacter baumannii
利用菌株历史改进对鲍曼不动杆菌抗菌药物耐药性演变的预测
- 批准号:
10677362 - 财政年份:2023
- 资助金额:
$ 114.2万 - 项目类别:
Inhibitors of adaptive efflux mediated resistance in Acinetobacter baumannii
鲍曼不动杆菌适应性外排介导的耐药性抑制剂
- 批准号:
10625029 - 财政年份:2023
- 资助金额:
$ 114.2万 - 项目类别:
Identifying niche specific adaptations in Acinetobacter baumannii
鉴定鲍曼不动杆菌的生态位特异性适应
- 批准号:
10596620 - 财政年份:2022
- 资助金额:
$ 114.2万 - 项目类别:
Identifying niche specific adaptations in Acinetobacter baumannii
鉴定鲍曼不动杆菌的生态位特异性适应
- 批准号:
10449699 - 财政年份:2022
- 资助金额:
$ 114.2万 - 项目类别:














{{item.name}}会员




